Journal of the European Academy of Dermatology and Venereology

Papers
(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Editor's Picks246
Pioneers in Dermatology and Venereology: an Interview with Professor David M. Pariser167
Pioneers in Dermatology and Venereology: An Interview with Professor Danilo V. Stevanovic156
Clinical evaluation of anaesthetic‐like effect of two dermocosmetic formulations containing Aquaphilus dolomiae extract‐G3 in subjects with sensitive facial skin156
Pioneers in Dermatology and Venereology: An Interview with Professor An Goossens137
Are non‐fungible tokens the barrier to realizing the Dermoverse?129
Announcement118
Announcement106
94
Announcement93
Editor's Picks January 202481
Commentary on vitiligo patient population and disease burden in France: VIOLIN Study results from the CONSTANCES cohort74
Announcement72
Issue Information71
Peer review, scientific publishing and the law of reciprocity65
65
Pioneers in Dermatology and Venereology: an interview with Professor Sarolta Kárpáti63
High prevalence of extracutaneous involvement in ITG junctional epidermolysis bullosa63
2013–2023: A decade of progress and challenges in dermatology as reflected in JEADV62
Two cases of cerebrovascular accidents following the induction dose of risankizumab61
A dermocosmetic product containing the sap of oat plantlets and Garcinia mangostana extract improves the clinical signs of acne61
Urinary incontinence and female genital lichen sclerosus58
Issue Information57
Announcement56
56
Contact allergy may enhance further sensitization to new chemicals, but individual susceptibility traits are important for polysensitization55
The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use54
Announcement49
Dalbavancin for the treatment of severe hidradenitis suppurativa49
Efficacy of imiquimod in the management of lentigo maligna48
Real‐life efficacy and safety of upadacitinib in adolescents with moderate‐to‐severe atopic dermatitis unresponsive to dupilumab: A case series47
A case of eruptive halo nevi following COVID‐1945
Pityriasis lichenoides et varioliformis acuta after SARS‐CoV‐2 infection and relapse after vaccination45
Barrier function‐related genes and proteins have an altered expression in acne‐involved skin45
Paradoxical joint and muscle pain in a patient treated with anifrolumab and belimumab44
Erythema multiforme major associated with molnupiravir treatment for SARS‐CoV‐2 infection: First report43
The chicken or the egg of lymphopenia in atopic eczema43
Genomic and antimicrobial resistance analyses of Neisseria gonorrhoeae isolates, Burkina Faso, 2018–201943
Dupilumab for the treatment of refractory allergic contact dermatitis from rubber/latex concomitant with atopic dermatitis42
Angiolymphoid hyperplasia with eosinophilia infiltrated by GATA3+ Th2 cells responding to dupilumab42
Two cases of anti‐TIF1‐γ antibody positive dermatomyositis with manifested symptoms after SARS‐CoV‐19 vaccination42
Assessing the efficacy of selective JAK inhibitors for alopecia areata with a patient‐centered approach42
The future of digital pills and their potential use in dermatological clinical trials42
0.055578947067261